Shire has entered an agreement to acquire SARcode Bioscience, Inc. for an upfront payment of $160 million and additional clinical, regulatory, and commercial milestones. The acquisition expands Shire’s ophthalmology portfolio with a Phase III compound LIFITEGRAST for the treatment of dry eye. Shire anticipates launching the drug in the U.S. as early as 2016. The transaction is expected to close in the second quarter, subject to customary closing conditions.    “The acquisition of SARcode i...